GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This approval broadens the previous indication for Jemperli plus chemotherapy in the European Union to include patients with mismatch repair proficient/microsatellite stable tumours, which represent approximately 75% of patients diagnosed with endometrial cancer and who have limited treatment options. The European Commission’s approval to expand the use of Jemperli plus chemotherapy is based on results from Part 1 of the RUBY phase III trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Novo Nordisk’s (NYSE:NVO) Ozempic and Wegovy Lined Up for Medicare Drug Price Negotiations
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- GSK to acquire IDRx for $1B upfront